Literature DB >> 29203211

QTc interval, cardiovascular events and mortality in patients with atrial fibrillation.

Andreas Reusser1, Steffen Blum2, Stefanie Aeschbacher1, Lucien Eggimann1, Peter Ammann3, Paul Erne4, Giorgio Moschovitis5, Marcello Di Valentino6, Dipen Shah7, Jürg Schläpfer8, Samuel Manser9, Tobias Reichlin1, Michael Kühne1, Christian Sticherling1, Stefan Osswald1, David Conen10.   

Abstract

BACKGROUND: A longer QTc interval has been associated with more adverse cardiovascular events and death in the general population. Little evidence is available on these relationships among patients with atrial fibrillation (AF).
METHODS: We performed a prospective observational multicenter cohort study of 1413 patients with AF. A resting 12‑lead electrocardiogram (ECG) was performed at baseline. QT interval was corrected for heart rate using the Bazett formula (QTc). Endpoints for this study included hospitalizations for congestive heart failure (CHF), a combination of cardiovascular death, myocardial infarction, stroke, systemic arterial embolism (MACE) and all-cause mortality.
RESULTS: Mean age of our population was 68±12years and 420 (30%) participants were female. Median QTc was 432ms (interquartile range 409; 457). The mean follow-up time was 3.6±1.5years. After multivariable adjustment, there was a linear increase in risk with increasing QTc interval for incident CHF (hazard ratio (HR) per 1-SD increase in QTc 1.3 [95% CI 1.1; 1.6], p=0.008), MACE (HR 1.2 [1.0; 1.4], p=0.02) and all-cause mortality (HR 1.3 [1.0; 1.6], p=0.002). Results were consistent whether or not patients were in sinus rhythm on the baseline ECG (HR for CHF 1.7 versus 1.3, p interaction 0.08; HR for MACE 1.3 versus 1.2, p interaction 0.9; HR for all-cause mortality 1.4 versus 1.4, p interaction 0.9).
CONCLUSIONS: In this large well-characterized cohort of AF patients, QTc interval was independently associated with adverse outcomes. These results were independent of the rhythm on the baseline ECG.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atrial fibrillation; Cardiovascular events; ECG; QTc interval

Mesh:

Year:  2017        PMID: 29203211     DOI: 10.1016/j.ijcard.2017.11.078

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

1.  Five-Year Outcomes and Cardiac Remodeling Following Left Atrial Appendage Occlusion.

Authors:  Baoxin Liu; Jiachen Luo; Mengmeng Gong; Zhiqiang Li; Beibei Shi; Xingxu Zhang; Xinqiang Han; Yidong Wei
Journal:  Clin Interv Aging       Date:  2021-04-19       Impact factor: 4.458

2.  Prognostic Significance of Prolonged Corrected QT Interval in Acute Ischemic Stroke.

Authors:  Sung-Ho Ahn; Ji-Sung Lee; Young-Hak Kim; Mi-Sook Yun; Jung-Hee Han; Soo-Young Kim; Min-Gyu Park; Kyung-Pil Park; Dong-Wha Kang; Jong S Kim; Sun U Kwon
Journal:  Front Neurol       Date:  2021-12-20       Impact factor: 4.003

3.  Association of QTc Interval with Risk of Cardiovascular Diseases and Related Vascular Traits: A Prospective and Longitudinal Analysis.

Authors:  Chanjuan Deng; Jingya Niu; Liping Xuan; Wen Zhu; Huajie Dai; Zhiyun Zhao; Mian Li; Jieli Lu; Yu Xu; Yuhong Chen; Weiqing Wang; Guang Ning; Yufang Bi; Min Xu; Tiange Wang
Journal:  Glob Heart       Date:  2020-02-10

4.  Effects of Lidocaine Oropharyngeal Spray Applied Before Endotracheal Intubation on QT Dispersion in Patients Undergoing Coronary Artery Bypass Grafting: A Prospective Randomized Controlled Study.

Authors:  Murat Bilgi; Yusuf Velioglu; Hamit Yoldas; Mehmet Cosgun; Ahmet Yuksel; Ibrahim Karagoz; Isa Yildiz; Abdulhamit Es; Duygu Caliskan; Kemalettin Erdem; Abdullah Demirhan
Journal:  Braz J Cardiovasc Surg       Date:  2020-06-01

5.  QT Interval Dynamics and Cardiovascular Outcomes: A Cohort Study in an Integrated Health Care Delivery System.

Authors:  Neha Mantri; Meng Lu; Jonathan G Zaroff; Neil Risch; Thomas Hoffmann; Akinyemi Oni-Orisan; Catherine Lee; Eric Jorgenson; Carlos Iribarren
Journal:  J Am Heart Assoc       Date:  2021-09-28       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.